XOMA Royalty (XOMA) Cost of Revenue (2012 - 2013)
XOMA Royalty (XOMA) reported Cost of Revenue of $21000.0 for Q2 2013, down 74.07% on a YoY basis from $81000.0 in Q2 2012, and down 54.35% sequentially from $46000.0 in Q1 2013.
XOMA Royalty (XOMA) Cost of Revenue (2012 - 2013) Analysis & Trends
XOMA Royalty (XOMA) has 2 years of Cost of Revenue data on file, last reported at $21000.0 in Q2 2013.
- For the quarter ending Q2 2013, Cost of Revenue fell 74.07% year-over-year to $21000.0; the trailing twelve-month figure through Jun 2013 stood at $128000.0 (up 58.02% YoY), and the FY2012 full-year result was $143000.0, changed N/A from the prior year.
- Cost of Revenue fell to $21000.0 in Q2 2013, from $46000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $81000.0 in Q2 2012 to a low of $21000.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 167.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 392.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 296.00 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 21,000.00 |
| Jun 30, 2013 | 21,000.00 |
| Mar 31, 2013 | 46,000.00 |
| Mar 31, 2013 | 46,000.00 |
| Dec 31, 2012 | 33,000.00 |
| Dec 31, 2012 | 33,000.00 |
| Sep 30, 2012 | 28,000.00 |
| Sep 30, 2012 | 28,000.00 |
| Jun 30, 2012 | 81,000.00 |
| Jun 30, 2012 | 81,000.00 |